SRRK

Scholar Rock is a clinical-stage biopharma whose value hinges almost entirely on apitegromab, an anti-myostatin antibody for spinal muscular atrophy (SMA). Critically, the efficacy risk is largely retired: the pivotal Phase 3 SAPPHIRE trial met its primary endpoint with a clinically meaningful, consistent benefit across subgroups, and the FDA granted priority review. The setback is regulatory/manufacturing, not scientific — in September 2025 the FDA issued a Complete Response Letter tied to cGMP observations at a third-party fill-finish facility (which received a warning letter), explicitly not citing apitegromab's efficacy or safety. Management plans to resubmit the BLA once the facility resolves the deficiencies, with an EMA MAA also in review.

Financially, this is a pre-revenue cash-burning enterprise. FY2025 had no product revenue, a net loss of -$378M (widening 53.5%), an operating loss of -$385M, and operating cash burn of -$300M. R&D rose 12.9% to $208M as the company built commercial and medical-affairs functions ahead of a launch that has now slipped. Cash of $324M (up 81.9% after raising capital, with shares up 21.3% and debt nearly doubled to $99.7M) covers only roughly a year of burn at the current rate — so additional dilutive financing is likely, especially with the launch delayed. Retained earnings are -$1.30B and ROE is -154%.